Oncology and Hematology - Global Oncology Academy

321-336 of 650

Balancing Efficacy and Tolerability in Metastatic Breast Cancer Treatment
Balancing Efficacy and Tolerability in Metastatic Breast Cancer Treatment
On the Frontlines of Metastatic Breast Cancer
Balancing Efficacy and Tolerability in Metastatic Breast Cancer Treatment
Paolo Tarantino, MD
- Paolo Tarantino, MD
Navigating Metastatic Breast Cancer Care: Key Factors in Decision-Making
Navigating Metastatic Breast Cancer Care: Key Factors in Decision-Making
On the Frontlines of Metastatic Breast Cancer
Navigating Metastatic Breast Cancer Care: Key Factors in Decision-Making
Paolo Tarantino, MD
- Paolo Tarantino, MD
Addressing Barriers to Colorectal Cancer Screening in Rural Populations
Addressing Barriers to Colorectal Cancer Screening in Rural Populations
Clinician's Roundtable
Addressing Barriers to Colorectal Cancer Screening in Rural Populations
Peter Buch, MD, FACG, AGAF, FACP; Michael Dougherty, MD
- Peter Buch, MD, FACG, AGAF, FACP
- Michael Dougherty, MD
Weighing the Environmental Impact of Colorectal Cancer Screening Methods
Weighing the Environmental Impact of Colorectal Cancer Screening Methods
Clinician's Roundtable
Weighing the Environmental Impact of Colorectal Cancer Screening Methods
Peter Buch, MD, FACG, AGAF, FACP; A. Mark Fendrick, MD
- Peter Buch, MD, FACG, AGAF, FACP
- A. Mark Fendrick, MD
Reducing Prostate Cancer Cell Production: The Role of Bipolar Androgen Therapy
Reducing Prostate Cancer Cell Production: The Role of Bipolar Androgen Therapy
On the Frontlines of Prostate Cancer
Reducing Prostate Cancer Cell Production: The Role of Bipolar Androgen Therapy
Mohit Khera, M.D., M.B.A., M.P.H.
- Mohit Khera, M.D., M.B.A., M.P.H.
Reducing Patient Time Burden in HER2+ Breast Cancer with Subcutaneous Trastuzumab/Pertuzumab
Reducing Patient Time Burden in HER2+ Breast Cancer with Subcutaneous Trastuzumab/Pertuzumab
Project Oncology®
Reducing Patient Time Burden in HER2+ Breast Cancer with Subcutaneous Trastuzumab/Pertuzumab
Prostate Cancer Care: Testosterone Therapy’s Impact on Biochemical Recurrence
Prostate Cancer Care: Testosterone Therapy’s Impact on Biochemical Recurrence
On the Frontlines of Prostate Cancer
Prostate Cancer Care: Testosterone Therapy’s Impact on Biochemical Recurrence
Mohit Khera, M.D., M.B.A., M.P.H.
- Mohit Khera, M.D., M.B.A., M.P.H.
Reevaluating Testosterone: A Paradigm Shift in Prostate Cancer Treatment
Reevaluating Testosterone: A Paradigm Shift in Prostate Cancer Treatment
On the Frontlines of Prostate Cancer
Reevaluating Testosterone: A Paradigm Shift in Prostate Cancer Treatment
Mohit Khera, M.D., M.B.A., M.P.H.
- Mohit Khera, M.D., M.B.A., M.P.H.
Examining the Role of Bacterial Biofilms in Colorectal Cancer Screening
Examining the Role of Bacterial Biofilms in Colorectal Cancer Screening
Clinician's Roundtable
Examining the Role of Bacterial Biofilms in Colorectal Cancer Screening
Early-Stage Prostate Cancer Treatment: Examining Long-Term Complications
Early-Stage Prostate Cancer Treatment: Examining Long-Term Complications
On the Frontlines of Prostate Cancer
Early-Stage Prostate Cancer Treatment: Examining Long-Term Complications
Joseph Unger, PhD, MS
- Joseph Unger, PhD, MS
Slowing Prostate Cancer Progression: The Role of Dietary Fat Modifications
Slowing Prostate Cancer Progression: The Role of Dietary Fat Modifications
On the Frontlines of Prostate Cancer
Slowing Prostate Cancer Progression: The Role of Dietary Fat Modifications
William Aronson, MD
- William Aronson, MD
Advancing Cancer Care: Key Considerations for Subcutaneous Immunotherapies
Advancing Cancer Care: Key Considerations for Subcutaneous Immunotherapies
Project Oncology®
Advancing Cancer Care: Key Considerations for Subcutaneous Immunotherapies
Charles Turck, PharmD, BCPS, BCCCP; Matthew Hadfield, MD
- Charles Turck, PharmD, BCPS, BCCCP
- Matthew Hadfield, MD
From Diagnosis to Treatment: Challenges in Glioblastoma Care
From Diagnosis to Treatment: Challenges in Glioblastoma Care
NeuroFrontiers
From Diagnosis to Treatment: Challenges in Glioblastoma Care
Lauren Schaff, MD
- Lauren Schaff, MD
Defining the Standard of Care and Optimal Sequencing in BRAF-Mutant mCRC: Second Line and Beyond
Defining the Standard of Care and Optimal Sequencing in BRAF-Mutant mCRC: Second Line and Beyond
MinuteCE®
Defining the Standard of Care and Optimal Sequencing in BRAF-Mutant mCRC: Second Line and Beyond
Fortunato Ciardiello, MD, PhD; Jenny Seligmann, MBChB, PhD
1.00 program credit
- Fortunato Ciardiello, MD, PhD
- Jenny Seligmann, MBChB, PhD
1.00 program credit
MinuteCE®
Mastering Mutation-Driven mCRC: From Testing to Targeted Therapy
Jenny Seligmann, MBChB, PhD; Fortunato Ciardiello, MD, PhD
1.00 credit 10 episodes
- Jenny Seligmann, MBChB, PhD
- Fortunato Ciardiello, MD, PhD
- Scott Kopetz, MD, PhD
- Cathy Eng, MD, FACP
1.00 credit 10 episodes
From Guidelines to Practice: First-Line Treatment Choices in mCRC
From Guidelines to Practice: First-Line Treatment Choices in mCRC
MinuteCE®
From Guidelines to Practice: First-Line Treatment Choices in mCRC
Fortunato Ciardiello, MD, PhD; Jenny Seligmann, MBChB, PhD
1.00 program credit
- Fortunato Ciardiello, MD, PhD
- Jenny Seligmann, MBChB, PhD
1.00 program credit

21/11